

Hyrnuo® (sevabertinib) Prior Authorization Form**Member Name:** _____ **Date of Birth:** _____ **Member ID#:** _____**Drug Information****Pharmacy Billing (NDC:** _____ **) Start Date (or date of next dose):** _____**Dose:** _____ **Regimen:** _____**Pharmacy Information****Pharmacy NPI:** _____ **Pharmacy Name:** _____**Pharmacy Phone:** _____ **Pharmacy Fax:** _____**Prescriber Information****Prescriber NPI:** _____ **Prescriber Name:** _____**Prescriber Phone:** _____ **Prescriber Fax:** _____ **Specialty:** _____**Criteria****For Initial Authorization:**

1. Please indicate the diagnosis and information:

☐ **Non-Small Cell Lung Cancer (NSCLC)**☐ **Other:** _____2. Is diagnosis non-squamous NSCLC? Yes ☐ No ☐3. Is disease locally advanced or metastatic? Yes ☐ No ☐4. Is disease positive for HER2 (ERBB2) tyrosine kinase domain activating mutations? Yes ☐ No ☐5. Has member received prior systemic therapy? Yes ☐ No ☐**Additional Information:** __________

_____**For Continued Authorization:**

1. Date of last dose: _____

2. Does member have any evidence of progressive disease while on sevabertinib? Yes ☐ No ☐3. Has the member experienced adverse drug reactions related to sevabertinib therapy? Yes ☐ No ☐*If yes, please specify adverse reactions:* _____

Prescriber Signature: _____ **Date:** _____***I certify that the indicated treatment is medically necessary and all information is true and correct to the best of my knowledge. Failure to complete this form in full will result in processing delays.***

Fax completed prior authorization request form to 888-601-8461 or submit Electronic Prior Authorization through CoverMyMeds® or SureScripts. All requested data must be provided. Incomplete forms or forms without the chart notes will be returned. Pharmacy Coverage Guidelines are available at AetnaBetterHealth.com/Oklahoma.

CONFIDENTIALITY NOTICE

This document, including any attachments, contains information which is confidential or privileged. If you are not the intended recipient, be aware that any disclosure, copying, distribution, or use of the contents of this information is prohibited. If you have received this document in error, please notify the sender immediately by telephone to arrange for the return of the transmitted documents or to verify their destruction.